Inflammasomes as therapeutic targets for Alzheimer's disease

Research output: Contribution to journalArticlepeer-review


Alzheimer's disease is the most common form of progressive dementia, typified initially by short term memory deficits which develop into a dramatic global cognitive decline. The classical hall marks of Alzheimer's disease include the accumulation of amyloid oligomers and fibrils, and the intracellular formation of neurofibrillary tangles of hyperphosphorylated tau. It is now clear that inflammation also plays a central role in the pathogenesis of the disease through a number of neurotoxic mechanisms. Microglia are the key immune regulators of the CNS which detect amyloidopathy through cell surface and cytosolic pattern recognition receptors (PRRs) and respond by initiating inflammation through the secretion of cytokines such as interleukin-1β (IL-1β). Inflammasomes, which regulate IL-1β release, are formed following activation of cytosolic PRRs, and using genetic and pharmacological approaches, NLRP3 and NLRP1 inflammasomes have been found to be integral in pathogenic neuroinflammation in animal models of Alzheimer's disease. Therefore, the inflammasomes are very promising novel pharmacological targets which merit further research in the continued endeavor for efficacious therapeutics for Alzheimer's disease.

Original languageEnglish
Pages (from-to)223-234
Number of pages12
JournalBrain Pathology
Issue number2
Early online date23 Dec 2016
Publication statusPublished - Mar 2017


  • Journal Article

Research Beacons, Institutes and Platforms

  • Dementia@Manchester
  • Lydia Becker Institute


Dive into the research topics of 'Inflammasomes as therapeutic targets for Alzheimer's disease'. Together they form a unique fingerprint.

Cite this